443 related articles for article (PubMed ID: 16397046)
21. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
22. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
[TBL] [Abstract][Full Text] [Related]
23. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
25. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
27. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
Zhao Y; Lu S; Wu L; Chai G; Wang H; Chen Y; Sun J; Yu Y; Zhou W; Zheng Q; Wu M; Otterson GA; Zhu WG
Mol Cell Biol; 2006 Apr; 26(7):2782-90. PubMed ID: 16537920
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
29. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
33. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
[TBL] [Abstract][Full Text] [Related]
34. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
35. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
Savickiene J; Borutinskaite VV; Treigyte G; Magnusson KE; Navakauskiene R
Eur J Pharmacol; 2006 Nov; 549(1-3):9-18. PubMed ID: 16978604
[TBL] [Abstract][Full Text] [Related]
36. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines.
Hartlapp I; Pallasch C; Weibert G; Kemkers A; Hummel M; Re D
Leuk Res; 2009 Jul; 33(7):929-36. PubMed ID: 19233470
[TBL] [Abstract][Full Text] [Related]
37. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
38. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
39. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Camphausen K; Scott T; Sproull M; Tofilon PJ
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]